Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure due to a potential error at the manufacturing site.
Similar Posts
Guidance: AI Airlock Simulation Workshops
Key insights of three simulation workshops from the AI Airlock pilot testing programme. Please note that these documents are not formal guidance.
Nirogacestat hydrobromide approved to treat desmoid tumours
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
Standard: Statement of Policy Intent: Early Access to Innovative Medical Devices
The MHRA’s initial plans on an Early Access service, which will be developed further throughout 2025.
Clinical trials for medicines: ending a clinical trial
Guidance on the process for ending a clinical trial.
National assessment procedure for medicines
Guidance on the MHRA’s national assessment procedure for marketing authorisation applications.
Promotional material: Vaccine safety – patient factsheet
Patient factsheet to provide information on vaccines and vaccine safety.